Autres langues Purple Biotech Ltd

Actions

PPBT

IL0007650166

Temps Différé TEL AVIV STOCK EXCHANGE Autres places de cotation 10:08:50 01/07/2024			Varia. 5j.	Varia. 1 janv.
16,7 ^ILa	-2,34%		-14,80%	-47,65%

27/06	Purple Biotech déclare que les données intermédiaires de l'étude sur le cancer du pancréas sont prometteuses	MT
27/06	Purple Biotech Ltd. Purple Biotech Ltd. annonce des résultats intermédiaires positifs supplémentaires de son étude de phase 2 randomisée sur le cancer du pancréas avec CM24 concernant un biomarqueur prédictif potentiel pour le bénéfice de la survie globale	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06
Purple Biotech : Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	27/06
Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	27/06
Purple Biotech : Immediate Report of Meeting	26/06
Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Form 6 K	26/06
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain of our present and former directors in February 2017	20/06
Purple Biotech : Immediate Report	05/06
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	01/06
Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer	01/06
Purple Biotech Reports First Quarter 2024 Financial Results	21/05
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28/03
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03
Purple Biotech : Immediate Report	06/03
6K:Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Purple Biotech Ltd

Actions

PPBT

IL0007650166

Autres langues

Filtres